UK Markets close in 1 hr 26 mins

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
7.03+0.26 (+3.89%)
As of 02:49PM GMT. Market open.
Full screen
Previous close6.76
Bid0.00 x 0
Ask0.00 x 0
Day's range7.00 - 7.40
52-week range7.00 - 7.40
Avg. volumeN/A
Market cap630.543M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-0.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

    Primary endpoint met with 99% seroresponse rate 12 months after single-dose vaccinationAntibody levels remained stable from month 6 to month 12No safety concern identified during follow-up, confirming the safety profile observed in earlier studiesValneva currently on track to complete rolling submission for Biologics License Application (BLA) with U.S. Food and Drug Administration (FDA) by end of 2022 Saint-Herblain (France), December 5, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a s

  • Zacks

    Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

    Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.

  • Globe Newswire

    Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

    Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination scheduleHigher antibody levels were observed in the three-dose vaccination schedule versus the two-dose vaccination schedule, further validating the use of this schedule in the ongoing Phase 3 studyThere were no safety concerns observed in this six-month observational follow up New York & Saint-Herblain (France), December 1, 2022 – Pfizer Inc. (NYSE: PFE) and Va